Skip to Main Content

INFORMATION FOR

Deborah Proctor, MD

Professor of Medicine (Digestive Diseases); Medical Director, Inflammatory Bowel Disease Program; Site Director, Universidad del Valle, Cali, Columbia and Yale/Stanford, Johnson and Johnson Global Health Scholar Program; President and Board of Directors, Honduras Children's Project, Internal Medicine

Research Summary

Our IBD Program group does clinical research with inflammatory bowel disease (IBD) patients including evaluating and treating depression in patients with inflammatory bowel disease and setting up databases to correlate genotype with phenotypic expression. We participate in several international multi-center trials for different medications and databases.

Our HHT group does clinical research in patients with hereditary hemorrhagic telangiectasia (HHT) who also have gastrointestinal (GI) bleeding.

Specialized Terms: Inflammatory Bowel Disease; Crohn's Disease; Ulcerative Colitis; Hereditary Hemorrhagic Telangiectasia

Extensive Research Description

Inflammatory bowel disease - our IBD Program group does clinical research with inflammatory bowel disease (IBD) patients including evaluating and treating depression in patients with inflammatory bowel disease and setting up databases to correlate genotype with phenotypic expression. We participate in several international multi-center trials for different medications and databases.

HHT - Along with other members of our HHT Center, our group does clinical research in patients with hereditary hemorrhagic telangiectasia (HHT) who also have gastrointestinal (GI) bleeding.

GI Match - Collaborating with other colleagues, we have done research on the GI fellowship match.

1. Treating depression in patients with inflammatory bowel disease

2. Multi-center trials for new drugs in inflammatory bowel disease

3. Correlation of genotype with phenotypic expression in patients with inflammatory bowel disease

4. Global health training attitudes in trainees

Coauthors

Research Interests

Colitis, Ulcerative; Crohn Disease; Gastrointestinal Hemorrhage; Ileitis; Rectal Fistula; Telangiectasia, Hereditary Hemorrhagic; Global Health; Inflammatory Bowel Diseases

Public Health Interests

Global Health

Research Images

Selected Publications

  • S856 Predictors of Colectomy in Acute Severe Ulcerative ColitisSharma S, Sharma S, Li D, Levine L, Chaar A, McMillan C, Gaidos J, Proctor D, Al-Bawardy B. S856 Predictors of Colectomy in Acute Severe Ulcerative Colitis The American Journal Of Gastroenterology 2022, 117: e618-e619. DOI: 10.14309/01.ajg.0000860064.59694.03.
  • S863 Impact of Race on ANTI-TNF Immunogenicity in Patients with Inflammatory Bowel DiseaseNawaz A, Nawaz A, Chaar A, Li D, Gaidos J, Proctor D, Al-Bawardy B. S863 Impact of Race on ANTI-TNF Immunogenicity in Patients with Inflammatory Bowel Disease The American Journal Of Gastroenterology 2022, 117: e623-e624. DOI: 10.14309/01.ajg.0000860092.19979.d5.
  • S862 Rates and Outcomes of Histologic Healing in Crohn's DiseaseMcMillan C, McMillan C, Levine L, Gaidos J, Proctor D, Al-Bawardy B, Jain D, Liang Y. S862 Rates and Outcomes of Histologic Healing in Crohn's Disease The American Journal Of Gastroenterology 2022, 117: e622-e623. DOI: 10.14309/01.ajg.0000860088.69814.32.
  • S875 Assessment of Inflammatory Bowel Disease Training Among Gastroenterology FellowsAl-Bawardy B, Al-Bawardy B, Malter L, Ehrlich A, Rieder F, Gaidos J, Proctor D, Windish D. S875 Assessment of Inflammatory Bowel Disease Training Among Gastroenterology Fellows The American Journal Of Gastroenterology 2022, 117: e632-e632. DOI: 10.14309/01.ajg.0000860140.96667.49.
  • 0573 Daytime and Nighttime Sleep and Symptoms of Depression and Anxiety in Adults with Inflammatory Bowel DiseaseConley S, Proctor D, Jeon S, Redeker N. 0573 Daytime and Nighttime Sleep and Symptoms of Depression and Anxiety in Adults with Inflammatory Bowel Disease Sleep 2022, 45: a252-a252. DOI: 10.1093/sleep/zsac079.570.
  • Mo1547: IMPACT OF EARLY VS DELAYED FLEXIBLE SIGMOIDOSCOPY ON OUTCOMES IN INPATIENT SEVERE ULCERATIVE COLITISSharma S, Levine L, McMillan C, Li D, Gaidos J, Proctor D, Bawardy B. Mo1547: IMPACT OF EARLY VS DELAYED FLEXIBLE SIGMOIDOSCOPY ON OUTCOMES IN INPATIENT SEVERE ULCERATIVE COLITIS Gastroenterology 2022, 162: s-813. DOI: 10.1016/s0016-5085(22)61919-x.
  • Tu1429: FREQUENCY AND CHARACTERISTICS OF NUTRITION ASSESSMENT IN HOSPITALIZED ULCERATIVE COLITIS PATIENTSLevine L, Sharma S, McMillan C, Li D, Gaidos J, Proctor D, Bawardy B. Tu1429: FREQUENCY AND CHARACTERISTICS OF NUTRITION ASSESSMENT IN HOSPITALIZED ULCERATIVE COLITIS PATIENTS Gastroenterology 2022, 162: s-957. DOI: 10.1016/s0016-5085(22)62267-4.
  • Gastrointestinal vascular malformations and neoplasms: arterial, venous, arteriovenous, and capillaryAl‐Bawardy B, Proctor D. Gastrointestinal vascular malformations and neoplasms: arterial, venous, arteriovenous, and capillary 2022, 2293-2314. DOI: 10.1002/9781119600206.ch113.
  • PREDICTORS AND OUTCOMES OF BIOLOGIC/IMMUNOSUPPRESSIVE THERAPY FOR PSC-ASSOCIATED IBDSayed A, Silveira M, Assis D, Deng Y, Gaidos J, Proctor D, Al-Bawardy B. PREDICTORS AND OUTCOMES OF BIOLOGIC/IMMUNOSUPPRESSIVE THERAPY FOR PSC-ASSOCIATED IBD Gastroenterology 2022, 162: s76. DOI: 10.1053/j.gastro.2021.12.161.
  • OUTCOMES OF TOTAL PROCTOCOLECTOMY (TPC) WITH ILEAL POUCH ANAL ANASTOMOSIS (IPAA)Petrov J, Al-Bawardy B, Gaidos J, Proctor D. OUTCOMES OF TOTAL PROCTOCOLECTOMY (TPC) WITH ILEAL POUCH ANAL ANASTOMOSIS (IPAA) Gastroenterology 2022, 162: s75-s76. DOI: 10.1053/j.gastro.2021.12.160.
  • IMPACT OF THIOPURINE DOSE IN COMBINATION THERAPY IN INFLAMMATORY BOWEL DISEASENawaz A, Glick L, Li D, Gaidos J, Proctor D, Al-Bawardy B. IMPACT OF THIOPURINE DOSE IN COMBINATION THERAPY IN INFLAMMATORY BOWEL DISEASE Gastroenterology 2022, 162: s107-s108. DOI: 10.1053/j.gastro.2021.12.221.
  • PREDICTORS AND OUTCOMES OF BIOLOGIC/IMMUNOSUPPRESSIVE THERAPY FOR PSC-ASSOCIATED IBDSayed A, Silveira M, Assis D, Deng Y, Gaidos J, Proctor D, Al-Bawardy B. PREDICTORS AND OUTCOMES OF BIOLOGIC/IMMUNOSUPPRESSIVE THERAPY FOR PSC-ASSOCIATED IBD Inflammatory Bowel Diseases 2022, 28: s76-s76. DOI: 10.1093/ibd/izac015.124.
  • OUTCOMES OF TOTAL PROCTOCOLECTOMY (TPC) WITH ILEAL POUCH ANAL ANASTOMOSIS (IPAA)Petrov J, Al-Bawardy B, Gaidos J, Proctor D. OUTCOMES OF TOTAL PROCTOCOLECTOMY (TPC) WITH ILEAL POUCH ANAL ANASTOMOSIS (IPAA) Inflammatory Bowel Diseases 2022, 28: s75-s76. DOI: 10.1093/ibd/izac015.123.
  • IMPACT OF THIOPURINE DOSE IN COMBINATION THERAPY IN INFLAMMATORY BOWEL DISEASENawaz A, Glick L, Li D, Gaidos J, Proctor D, Al-Bawardy B. IMPACT OF THIOPURINE DOSE IN COMBINATION THERAPY IN INFLAMMATORY BOWEL DISEASE Inflammatory Bowel Diseases 2022, 28: s107-s108. DOI: 10.1093/ibd/izac015.174.
  • The Impact of Inflammatory Bowel Disease Clinic On-site Vaccination ServicesHussain N, Proctor D, Al-Bawardy B. The Impact of Inflammatory Bowel Disease Clinic On-site Vaccination Services Crohn's & Colitis 360 2021, 3: otab067-. DOI: 10.1093/crocol/otab067.
  • Su465 EFFECT OF OBESITY ON VEDOLIZUMAB RESPONSE IN INFLAMMATORY BOWEL DISEASELevine L, Gaidos J, Proctor D, Viana A, Bawardy B. Su465 EFFECT OF OBESITY ON VEDOLIZUMAB RESPONSE IN INFLAMMATORY BOWEL DISEASE Gastroenterology 2021, 160: s-703-s-704. DOI: 10.1016/s0016-5085(21)02387-8.
  • Sa566 OUTCOMES OF INFLAMMATORY BOWEL DISEASE WITH CONCOMITANT ADVANCED LIVER FIBROSIS AND CIRRHOSISLi M, Khan S, Gaidos J, Proctor D, Bawardy B. Sa566 OUTCOMES OF INFLAMMATORY BOWEL DISEASE WITH CONCOMITANT ADVANCED LIVER FIBROSIS AND CIRRHOSIS Gastroenterology 2021, 160: s-554. DOI: 10.1016/s0016-5085(21)02022-9.
  • Su464 PREDICTORS AND OUTCOMES OF VEDOLIZUMAB DOSE ESCALATION IN INFLAMMATORY BOWEL DISEASELevine L, Gaidos J, Proctor D, Bawardy B. Su464 PREDICTORS AND OUTCOMES OF VEDOLIZUMAB DOSE ESCALATION IN INFLAMMATORY BOWEL DISEASE Gastroenterology 2021, 160: s-703. DOI: 10.1016/s0016-5085(21)02386-6.
  • THE SAFETY, TOLERABILITY, AND EFFECTIVENESS OF BIOLOGICS/SMALL MOLECULE THERAPY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND CIRRHOSISLi M, Khan S, Proctor D, Gaidos J, Al-Bawardy B. THE SAFETY, TOLERABILITY, AND EFFECTIVENESS OF BIOLOGICS/SMALL MOLECULE THERAPY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND CIRRHOSIS Gastroenterology 2021, 160: s62. DOI: 10.1053/j.gastro.2021.01.159.
  • THE SAFETY, TOLERABILITY, AND EFFECTIVENESS OF BIOLOGICS/SMALL MOLECULE THERAPY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND CIRRHOSISLi M, Khan S, Proctor D, Gaidos J, Al-Bawardy B. THE SAFETY, TOLERABILITY, AND EFFECTIVENESS OF BIOLOGICS/SMALL MOLECULE THERAPY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND CIRRHOSIS Inflammatory Bowel Diseases 2021, 27: s45-s46. DOI: 10.1093/ibd/izaa347.110.
  • S0709 IBD Clinic On-Site Vaccination Services and Vaccination Completion Rates in Patients With Inflammatory Bowel DiseaseHussain N, Proctor D, Ruggiero E, Al-Bawardy B. S0709 IBD Clinic On-Site Vaccination Services and Vaccination Completion Rates in Patients With Inflammatory Bowel Disease The American Journal Of Gastroenterology 2020, 115: s356-s356. DOI: 10.14309/01.ajg.0000704884.71749.ca.
  • S0830 The Impact of Vedolizumab on Pre-Existing Extraintestinal Manifestations of Inflammatory Bowel Disease: A Multicenter StudyRamos G, Dimopoulos C, McDonald N, Janssens L, Hung K, Proctor D, Ruggiero E, Bruning D, Faubion W, Raffals L, Loftus E, Al-Bawardy B. S0830 The Impact of Vedolizumab on Pre-Existing Extraintestinal Manifestations of Inflammatory Bowel Disease: A Multicenter Study The American Journal Of Gastroenterology 2020, 115: s427-s428. DOI: 10.14309/01.ajg.0000705368.24314.98.
  • Su1852 EFFECTS OF VEDOLIZUMAB ON EXTRAINTESTINAL MANIFESTATIONS IN INFLAMMATORY BOWEL DISEASEDimopoulos C, Hung K, Proctor D, Ruggiero E, Al-Bawardy B. Su1852 EFFECTS OF VEDOLIZUMAB ON EXTRAINTESTINAL MANIFESTATIONS IN INFLAMMATORY BOWEL DISEASE Gastroenterology 2020, 158: s-675. DOI: 10.1016/s0016-5085(20)32379-9.
  • 23 EFFECTS OF VEDOLIZUMAB ON EXTRAINTESTINAL MANIFESTATIONS IN INFLAMMATORY BOWEL DISEASEDimopoulos C, Hung K, Proctor D, Ruggiero E, Al-Bawardy B. 23 EFFECTS OF VEDOLIZUMAB ON EXTRAINTESTINAL MANIFESTATIONS IN INFLAMMATORY BOWEL DISEASE Gastroenterology 2020, 158: s32-s33. DOI: 10.1053/j.gastro.2019.11.107.
  • P099 LEUKOCYTOCLASTIC VASCULITIS AFTER USTEKINUMAB INDUCTION IN CROHN'S DISEASE: A CASE SERIES AND SYSTEMATIC REVIEWChugh R, Proctor D, Little A, Myung P, Imaeda S, Al-Bawardy B. P099 LEUKOCYTOCLASTIC VASCULITIS AFTER USTEKINUMAB INDUCTION IN CROHN'S DISEASE: A CASE SERIES AND SYSTEMATIC REVIEW Gastroenterology 2020, 158: s3. DOI: 10.1053/j.gastro.2019.11.046.
  • 23 EFFECTS OF VEDOLIZUMAB ON EXTRAINTESTINAL MANIFESTATIONS IN INFLAMMATORY BOWEL DISEASEDimopoulos C, Hung K, Proctor D, Ruggiero E, Al-Bawardy B. 23 EFFECTS OF VEDOLIZUMAB ON EXTRAINTESTINAL MANIFESTATIONS IN INFLAMMATORY BOWEL DISEASE Inflammatory Bowel Diseases 2020, 26: s19-s20. DOI: 10.1093/ibd/zaa010.047.
  • P099 LEUKOCYTOCLASTIC VASCULITIS AFTER USTEKINUMAB INDUCTION IN CROHN’S DISEASE: A CASE SERIES AND SYSTEMATIC REVIEWChugh R, Proctor D, Little A, Myung P, Imaeda S, Al-Bawardy B. P099 LEUKOCYTOCLASTIC VASCULITIS AFTER USTEKINUMAB INDUCTION IN CROHN’S DISEASE: A CASE SERIES AND SYSTEMATIC REVIEW Inflammatory Bowel Diseases 2020, 26: s2-s2. DOI: 10.1093/ibd/zaa010.004.
  • 0636 Activity-Rest Patterns and Symptoms in Inflammatory Bowel DiseaseConley S, Conley S, Jeon S, Lehner V, Lehner V, Proctor D, Redeker N. 0636 Activity-Rest Patterns and Symptoms in Inflammatory Bowel Disease Sleep 2019, 42: a253-a253. DOI: 10.1093/sleep/zsz067.634.
  • THREE TYPES OF INTRAHEPATIC SHUNTS PRESENTING IN A SINGLE PATIENT WITH HEREDITARY HEMORRHAGIC TELANGIECTASIABrandt E, Haghighat L, Garcia-Tsao G, Henderson K, Pollak J, Proctor D, Young L. THREE TYPES OF INTRAHEPATIC SHUNTS PRESENTING IN A SINGLE PATIENT WITH HEREDITARY HEMORRHAGIC TELANGIECTASIA Journal Of The American College Of Cardiology 2018, 71: a2393. DOI: 10.1016/s0735-1097(18)32934-6.
  • Bernasko N, Proctor D. Invited commentary. Characteristics and Behavior of Elderly-Onset Inflammatory Bowel Disease: A Multi-Center US Study. PracticeUpdate website. Available at: http://www.practiceupdate.com/content/characteristics-and-behavior-of-elderly-onset-inflammatory-bowel-disease/43340/65/9/1. Accessed September 08, 2016. Bernasko N, Proctor D. Invited commentary. Characteristics and Behavior of Elderly-Onset Inflammatory Bowel Disease: A Multi-Center US Study. PracticeUpdate website. Available at: http://www.practiceupdate.com/content/characteristics-and-behavior-of-elderly-onset-inflammatory-bowel-disease/43340/65/9/1. Accessed September 08, 2016.
  • Tu1112 Global Health Curriculum in Gastroenterology Fellowship: A National SurveyJirapinyo P, Tabak Y, Hunt R, Proctor D, Makrauer F. Tu1112 Global Health Curriculum in Gastroenterology Fellowship: A National Survey Gastroenterology 2015, 148: s-791. DOI: 10.1016/s0016-5085(15)32700-1.
  • Erratum: EMerging BiomARKers in Inflammatory Bowel Disease (EMBARK) Study Identifies Fecal Calprotectin, Serum MMP9, and Serum IL-22 as a Novel Combination of Biomarkers for Crohn's Disease Activity: Role of Cross-Sectional ImagingFaubion W, Fletcher J, O'Byrne S, Feagan B, de Villiers W, Salzberg B, Plevy S, Proctor D, Valentine J, Higgins P, Harris J, Diehl L, Wright L, Tew G, Luca D, Basu K, Keir M. Erratum: EMerging BiomARKers in Inflammatory Bowel Disease (EMBARK) Study Identifies Fecal Calprotectin, Serum MMP9, and Serum IL-22 as a Novel Combination of Biomarkers for Crohn's Disease Activity: Role of Cross-Sectional Imaging The American Journal Of Gastroenterology 2014, 109: 780. DOI: 10.1038/ajg.2014.69.
  • 565 Appendectomy and Extensive Disease Are Independent Predictors of Colectomy in Ulcerative Colitis: Results From a Large Cross-Sectional CohortParian A, Limketkai B, Koh J, Brant S, Bitton A, Cho J, Duerr R, McGovern D, Proctor D, Regueiro M, Rioux J, Schumm L, Taylor K, Silverberg M, Steinhart A, Lazarev M. 565 Appendectomy and Extensive Disease Are Independent Predictors of Colectomy in Ulcerative Colitis: Results From a Large Cross-Sectional Cohort Gastroenterology 2013, 144: s-105. DOI: 10.1016/s0016-5085(13)60385-6.
  • Mo1241 Patterns of Extraintestinal Manifestations in Ulcerative Colitis and Crohn's Disease: Results From a Large Cross-Sectional CohortKoh J, Limketkai B, Parian A, Brant S, Bitton A, Cho J, Duerr R, McGovern D, Proctor D, Regueiro M, Rioux J, Schumm L, Taylor K, Silverberg M, Steinhart A, Lazarev M. Mo1241 Patterns of Extraintestinal Manifestations in Ulcerative Colitis and Crohn's Disease: Results From a Large Cross-Sectional Cohort Gastroenterology 2013, 144: s-615. DOI: 10.1016/s0016-5085(13)62274-x.
  • Sa1248 Late Adult-Onset Inflammatory Bowel Disease Patients Require Surgery Earlier During Their Disease Course Compared to Early Adult-Onset PatientsHa C, Bayless T, Bitton A, Cho J, Duerr R, McGovern D, Proctor D, Regueiro M, Rioux J, Schumm L, Taylor K, Silverberg M, Steinhart A, Brant S. Sa1248 Late Adult-Onset Inflammatory Bowel Disease Patients Require Surgery Earlier During Their Disease Course Compared to Early Adult-Onset Patients Gastroenterology 2012, 142: s-253-s-254. DOI: 10.1016/s0016-5085(12)60955-x.
  • Mo1680 Assessing Crohn's Disease Inflammatory Biomarker Diagnostic Accuracy Using Ileocolonoscopy or a Combined Ileocolonoscopy-CTE Score in the Embark StudyFaubion W, Fletcher J, de Villiers W, Salzberg B, Plevy S, Proctor D, Valentine J, Feagan B, Higgins P, Harris J, Luca D, O'Byrne S, Keir M. Mo1680 Assessing Crohn's Disease Inflammatory Biomarker Diagnostic Accuracy Using Ileocolonoscopy or a Combined Ileocolonoscopy-CTE Score in the Embark Study Gastroenterology 2012, 142: s-658. DOI: 10.1016/s0016-5085(12)62535-9.
  • 760 Divergence in L4 Crohn's Disease: Jejunal, Not Esophagogastroduodenal Involvement, is Protective of L2 Disease Location, and a Risk for Stricturing Behavior and Multiple Abdominal Surgeries. Report From the NIDDK-IBDGC RegistryLazarev M, Hutfless S, Bitton A, Cho J, Duerr R, McGovern D, Proctor D, Regueiro M, Rioux J, Schumm P, Taylor K, Silverberg M, Steinhart H, Brant S. 760 Divergence in L4 Crohn's Disease: Jejunal, Not Esophagogastroduodenal Involvement, is Protective of L2 Disease Location, and a Risk for Stricturing Behavior and Multiple Abdominal Surgeries. Report From the NIDDK-IBDGC Registry Gastroenterology 2010, 138: s-105. DOI: 10.1016/s0016-5085(10)60481-7.
  • ChemInform Abstract: Spectrum of Histologic Changes in Colonic Biopsies in Patients Treated with Mycophenolate MofetilSelbst M, Ahrens W, Robert M, Friedman A, Proctor D, Jain D. ChemInform Abstract: Spectrum of Histologic Changes in Colonic Biopsies in Patients Treated with Mycophenolate Mofetil ChemInform 2010, 41: no-no. DOI: 10.1002/chin.201010274.
  • Does Treatment of Inflammatory Bowel Disease Prevent Cancer?West B, Proctor D, Itzkowitz S, Loftus E, Nair P. Does Treatment of Inflammatory Bowel Disease Prevent Cancer? Journal Of Clinical Gastroenterology 2003, 36: s94-s96. DOI: 10.1097/00004836-200305001-00016.
  • Absence of c-kit + cells in resected segments of patients with chronic intestinal pseudo-obstruction (CIIP)Moussa K, Proctor D, Jain D, Culpepper-Morgan J. Absence of c-kit + cells in resected segments of patients with chronic intestinal pseudo-obstruction (CIIP) Gastroenterology 2000, 118: a866. DOI: 10.1016/s0016-5085(00)85606-1.
  • Missionary work – it’s about more than doing endoscopies.Proctor DD. Missionary work – it’s about more than doing endoscopies. AGA Perspectives 2013;9(3):22-23.
  • Rockey DC, Harrison SA, Wong RKH, Schiller LR, Proctor DD, Wolfe MM, Chutkan R, Vargo JJ, Waxler A. The gastroenterology core curriculum, third edition – May 2007. Gastroenterology 2007132(5):2012-2018. Rockey DC, Harrison SA, Wong RKH, Schiller LR, Proctor DD, Wolfe MM, Chutkan R, Vargo JJ, Waxler A. The gastroenterology core curriculum, third edition – May 2007. Gastroenterology 2007132(5):2012-2018.

Clinical Trials

ConditionsStudy Title
Diseases of the Digestive System - Small Intestines, Large Intestines & RectumA Study to Assess the Genotype of Subjects with Diagnosis of Ulcerative Colitis or Crohn's Disease (The PRELUDE Study)
Diseases of the Digestive System - Small Intestines, Large Intestines & RectumAn Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease
Diseases of the Digestive System - Small Intestines, Large Intestines & Rectum; Diseases of the Digestive System - StomachInduction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease
Diseases of the Digestive System - Small Intestines, Large Intestines & RectumA Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease